Syn­dax's menin in­hibitor suc­ceeds in piv­otal tri­al, but in­vestors aren't im­pressed

Syn­dax Phar­ma­ceu­ti­cals said its ex­per­i­men­tal menin in­hibitor met the pri­ma­ry end­point in a piv­otal tri­al for cer­tain leukemia pa­tients, and it’s plan­ning a reg­u­la­to­ry fil­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER